Cowden Syndrome - Disorder Mechanisms

◆

Subtypes

4

Cowden Syndrome 1 (PTEN)

Classic Cowden syndrome caused by germline loss-of-function mutations in PTEN on chromosome 10q22-23, accounting for approximately 80% of cases meeting strict clinical diagnostic criteria. Mutations include nonsense, frameshift, missense, splice-site variants, and large deletions.

Show evidence (1 reference)

PMID:24136893 SUPPORT Human Clinical

"Although it was initially reported that approximately 80% of patients with Cowden syndrome had an identifiable germline PTEN mutation, more recent work has shown these diagnostic criteria to be far less specific."

Establishes PTEN mutation as the predominant genetic cause in Cowden syndrome 1, noting that original ~80% frequency estimates derived from clinically ascertained cohorts.

Cowden Syndrome 2 (KLLN)

Cowden syndrome caused by germline epigenetic silencing (promoter hypermethylation) of KILLIN (KLLN), a p53-co-regulated tumor suppressor transcribed from the same bidirectional promoter as PTEN. KLLN methylation down-regulates KILLIN expression and is associated with increased breast and renal cancer risk.

Show evidence (1 reference)

PMID:21177507 SUPPORT Human Clinical

"Germline KILLIN methylation is common among patients with Cowden syndrome or Cowden-like syndrome and is associated with increased risks of breast and renal cancer over PTEN mutation-positive individuals."

Defines KLLN germline epigenetic silencing as the second major cause of Cowden/Cowden-like syndrome, conferring higher breast and kidney cancer risk than PTEN mutation alone.

Cowden Syndrome 3 (PIK3CA)

Cowden syndrome caused by activating germline mutations in PIK3CA, the catalytic subunit of PI3-kinase. PIK3CA mutations are found in approximately 8.8% of PTEN mutation-negative Cowden syndrome individuals and result in elevated PIP3 and activated AKT, mimicking PTEN loss.

Show evidence (1 reference)

PMID:23246288 SUPPORT Human Clinical

"Our observations suggest that PIK3CA and AKT1 are CS susceptibility genes."

Identifies PIK3CA germline mutations as a causative alternative to PTEN in Cowden syndrome 3, acting through the same PI3K/AKT signaling axis.

Cowden Syndrome 4 (SDHB)

Cowden syndrome caused by germline mutations in succinate dehydrogenase subunit B (SDHB). SDH mutations alter mitochondrial metabolism, stabilize HIF-1alpha through pseudohypoxia, and activate downstream PI3K/AKT/MAPK signaling in the absence of PTEN mutation.

Show evidence (1 reference)

PMID:18678321 SUPPORT Human Clinical

"Germline SDH mutations/variants occur in a subset of PTEN mutation-negative CS/CS-like individuals and are associated with increased frequencies of breast, thyroid, and renal cancers beyond those conferred by germline PTEN mutations."

Establishes SDHB germline mutations as a causative factor in Cowden/Cowden-like syndrome in PTEN-mutation-negative individuals with elevated cancer risk.

⚙

Pathophysiology

3

PTEN Loss and PI3K/AKT/mTOR Pathway Activation

PTEN (phosphatase and tensin homolog) is a tumor suppressor that dephosphorylates phosphatidylinositol-3,4,5-trisphosphate (PIP3) to PIP2, thereby inhibiting the PI3K/AKT/mTOR signaling axis. Germline loss-of-function mutations in PTEN lead to constitutive accumulation of PIP3 and unopposed activation of AKT and downstream mTOR complex 1 (mTORC1), resulting in excessive cell proliferation, survival, and growth that underlies hamartoma formation and elevated cancer risk across multiple organ systems.

Epithelial cell link Fibroblast link

PI3K/AKT signaling link ↑ INCREASED TOR signaling link ↑ INCREASED Cell proliferation link ↑ INCREASED Negative regulation of apoptosis link ↑ INCREASED

Show evidence (2 references)

PMID:18781191 SUPPORT Human Clinical

"PTEN is located on chromosome 10q22-23 and negatively regulates the prosurvival PI3K/Akt/mTOR pathway through its lipid phosphatase activity. Loss of PTEN activates this pathway and leads to increased cellular growth, migration, proliferation, and survival."

Directly establishes that PTEN loss leads to PI3K/AKT/mTOR hyperactivation driving cellular overgrowth, the central molecular mechanism of Cowden syndrome.

PMID:30614812 SUPPORT Human Clinical

"The tumor suppressor phosphatase and tensin homolog (PTEN) classically counteracts the PI3K/AKT/mTOR signaling cascade. Germline pathogenic PTEN mutations cause PTEN hamartoma tumor syndrome (PHTS), featuring various benign and malignant tumors, as well as neurodevelopmental disorders such as..."

Confirms PTEN's role as a counterbalance to PI3K/AKT/mTOR and links germline PTEN mutations to the full PHTS spectrum including Cowden syndrome.

Hamartoma Formation

Constitutive activation of PI3K/AKT/mTOR signaling in multiple cell lineages drives the abnormal but organized proliferation of tissue elements native to the affected site, producing hamartomas. In Cowden syndrome these manifest as mucocutaneous trichilemmomas, papillomatous papules, acral keratoses, gastrointestinal hamartomatous polyps, and thyroid adenomas. The hamartomas are histologically benign but serve as a marker of systemic PTEN dysfunction and elevated cancer predisposition.

Keratinocyte link Thyroid follicular cell link

Hamartomatous cell proliferation link ↑ INCREASED

Show evidence (1 reference)

PMID:18781191 SUPPORT Human Clinical

"The PTEN hamartoma tumor syndromes (PHTS) are a collection of rare clinical syndromes characterized by germline mutations of the tumor suppressor PTEN. These syndromes are driven by cellular overgrowth, leading to benign hamartomas in virtually any organ."

Confirms that PTEN loss drives cellular overgrowth leading to hamartomas across organ systems, which is the hallmark of Cowden syndrome pathology.

Increased Cancer Risk

The same PI3K/AKT/mTOR over-activation that drives benign hamartoma formation also confers markedly elevated lifetime risks for malignancies. The cumulative lifetime risk in PTEN mutation carriers includes breast cancer (~77-85%), follicular/papillary thyroid cancer (~35-38%), endometrial cancer (~28%), renal cell carcinoma (~34%), and colorectal cancer (~9-16%). Second-hit somatic mutations or epigenetic silencing of the remaining wild-type PTEN allele accelerate neoplastic progression.

Cell proliferation link ↑ INCREASED

Show evidence (2 references)

PMID:23335809 SUPPORT Human Clinical

"Cumulative cancer risks at age 70 were 85% (95% CI 70% to 95%) for any cancer, 77% (95% CI 59% to 91%) for female breast cancer, and 38% (95% CI 25% to 56%) for thyroid cancer."

Quantifies the markedly elevated cumulative cancer risks in PTEN mutation carriers, establishing the clinical significance of increased cancer risk in PHTS/Cowden syndrome.

PMID:32533092 SUPPORT Human Clinical

"The projected estimated lifetime risks of cancer in individuals with PHTS range from 85 to 89% for any cancer, 67 to 85% for female breast cancer, 6 to 38% for thyroid cancer, 2 to 28% for endometrial cancer, 2 to 34% for renal cancer, 9 to 20% for colorectal cancer and 0 to 6% for melanoma."

Provides European expert consensus estimates for organ-specific lifetime cancer risks in PHTS/Cowden syndrome, supporting the multi-organ cancer predisposition mechanism.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

7

Breast 1

Breast Cancer Risk Breast carcinoma (HP:0003002)

Show evidence (1 reference)

PMID:23335809 SUPPORT Human Clinical

"Elevated SIRs were found mainly for female breast cancer (39.1, 95% CI 24.8 to 58.6), thyroid cancer in women (43.2, 95% CI 19.7 to 82.1) and in men (199.5, 95% CI 106.39 to 342.03), melanoma in women (28.3, 95% CI 7.6 to 35.4) and in men (39.4, 95% CI 10.6 to 100.9), and endometrial cancer..."

Demonstrates markedly elevated standardized incidence ratios (SIR 39.1) for breast cancer in female PTEN mutation carriers, confirming the substantially increased breast cancer risk in Cowden syndrome.

Digestive 1

Gastrointestinal Hamartomatous Polyps Hamartomatous polyposis (HP:0004390)

Show evidence (1 reference)

PMID:32533092 SUPPORT Human Clinical

"Polyps are common in PHTS, and these are typically hamartomas, although other types can also occur."

Confirms hamartomatous GI polyps as a common feature of PTEN hamartoma tumor syndrome/Cowden syndrome.

Endocrine 1

Thyroid Abnormalities Thyroid carcinoma (HP:0002890)

Show evidence (1 reference)

PMID:32533092 SUPPORT Human Clinical

"There is strong evidence of an increased risk of thyroid carcinoma in PHTS with evidence that this can arise at relatively young ages."

Confirms strong clinical evidence for increased thyroid carcinoma risk in PTEN hamartoma tumor syndrome/Cowden syndrome.

Genitourinary 1

Uterine Cancer Risk Endometrial carcinoma (HP:0012114)

Show evidence (1 reference)

PMID:23335809 SUPPORT Human Clinical

"Elevated SIRs were found mainly for female breast cancer (39.1, 95% CI 24.8 to 58.6), thyroid cancer in women (43.2, 95% CI 19.7 to 82.1) and in men (199.5, 95% CI 106.39 to 342.03), melanoma in women (28.3, 95% CI 7.6 to 35.4) and in men (39.4, 95% CI 10.6 to 100.9), and endometrial cancer..."

Documents a substantially elevated standardized incidence ratio (SIR 48.7) for endometrial cancer in PHTS, confirming uterine cancer as a major cancer risk in Cowden syndrome.

Head and Neck 1

Macrocephaly Macrocephaly (HP:0000256)

Show evidence (1 reference)

PMID:17526800 SUPPORT Human Clinical

"Bannayan-Riley-Ruvalcaba syndrome (BRRS), with childhood onset, macrocephaly, lipomas and developmental delay, and Cowden Syndrome (CS), an adult-onset condition recognised by mucocutaneous signs, with a risk of cancers, in particular those of the thyroid and breast."

Documents macrocephaly as a characteristic feature across the PTEN mutation phenotypic spectrum, particularly in the childhood-onset BRRS form.

Nervous System 1

Lhermitte-Duclos Disease Dysplastic gangliocytoma of the cerebellum (HP:0500009)

Show evidence (1 reference)

PMID:37810307 SUPPORT Human Clinical

"Lhermitte-Duclos disease (LDD) is a rare tumor, with only about 300 reported cases. It often shows comorbidity with Cowden syndrome (CS); however, it can occur by itself."

Confirms the well-established association between Lhermitte-Duclos disease and Cowden syndrome in a systematic review of 302 cases, with 32.8% of LDD showing CS comorbidity.

Neoplasm 1

Mucocutaneous Lesions Hamartoma (HP:0010566)

Show evidence (1 reference)

PMID:17526800 SUPPORT Human Clinical

"Cowden Syndrome (CS), an adult-onset condition recognised by mucocutaneous signs, with a risk of cancers, in particular those of the thyroid and breast."

Establishes mucocutaneous signs as the defining clinical feature of Cowden syndrome in PTEN mutation carriers.

🧬

Genetic Associations

4

PTEN (Causative)

Autosomal dominant

Show evidence (1 reference)

PMID:21194675 SUPPORT Human Clinical

"Cowden syndrome (CS) and Bannayan-Riley-Ruvalcaba syndrome are allelic, defined by germline PTEN mutations, and collectively referred to as PTEN hamartoma tumor syndrome."

Establishes PTEN germline mutations as the defining genetic cause of Cowden syndrome in a large prospective cohort of 3042 probands.

KLLN (Causative)

Autosomal dominant

Show evidence (1 reference)

PMID:21177507 SUPPORT Human Clinical

"Germline KILLIN methylation is common among patients with Cowden syndrome or Cowden-like syndrome and is associated with increased risks of breast and renal cancer over PTEN mutation-positive individuals."

Establishes KLLN germline methylation as a distinct molecular subtype of Cowden syndrome with measurably elevated cancer risks.

PIK3CA (Causative)

Autosomal dominant

Show evidence (1 reference)

PMID:23246288 SUPPORT Human Clinical

"We report that 8 of 91 (8.8%) unrelated CS individuals without germline PTEN mutations carried 10 germline PIK3CA mutations (7 missense, 1 nonsense, and 2 indels) and 2 (2.2%) AKT1 mutations. These mutations result in significantly increased P-Thr308-AKT and increased cellular PIP3."

Directly identifies PIK3CA germline mutations in Cowden syndrome patients lacking PTEN mutations, confirming PIK3CA as a causative gene in Cowden syndrome 3.

SDHB (Causative)

Autosomal dominant

Show evidence (1 reference)

PMID:18678321 SUPPORT Human Clinical

"Germline SDH mutations/variants occur in a subset of PTEN mutation-negative CS/CS-like individuals and are associated with increased frequencies of breast, thyroid, and renal cancers beyond those conferred by germline PTEN mutations."

Establishes SDHB germline mutations as a causative factor in Cowden syndrome 4, found in PTEN-mutation-negative individuals with elevated cancer risk.

💊

Treatments

4

Enhanced Cancer Surveillance

Action: cancer surveillance Ontology label: cancer screening MAXO:0000126

PTEN mutation carriers require life-long intensified surveillance protocols: annual MRI breast screening from age 30, annual thyroid ultrasound from age 18, renal ultrasound every 2 years from age 40, and baseline colonoscopy at age 35-40. These recommendations are based on European expert consensus (ERN GENTURIS, 2020).

Show evidence (1 reference)

PMID:32533092 SUPPORT Human Clinical

"Recommendations were put forward for surveillance for breast, thyroid and renal cancers. Limited recommendations were developed for other sites including endometrial, colon and skin."

Provides evidence-based surveillance recommendations for PHTS/Cowden syndrome from the European Reference Network for Genetic Tumour Risk Syndromes.

Prophylactic Mastectomy

Action: prophylactic mastectomy Ontology label: surgical procedure MAXO:0000004

Risk-reducing bilateral mastectomy reduces breast cancer risk by more than 90% in PTEN mutation carriers with high personal or family risk. It is offered as an option after careful counseling regarding elevated lifetime risk, using the same approach as for BRCA1/BRCA2 carriers.

Show evidence (1 reference)

PMID:32533092 SUPPORT Human Clinical

"Risk reduction surgery should be offered using the same considerations as for women with germline BRCA1/BRCA2 pathogenic variants"

Supports offering prophylactic mastectomy in PTEN mutation carriers following the same approach as for BRCA1/BRCA2, given comparable breast cancer risk levels.

mTOR Inhibitor Therapy

Action: mTOR inhibitor pharmacotherapy Ontology label: pharmacotherapy MAXO:0000058

Everolimus (RAD001), an mTORC1 inhibitor, targets the hyperactivated PI3K/AKT/mTOR pathway in Cowden syndrome. The rationale for PI3K pathway inhibitors in PHTS stems directly from the underlying molecular pathophysiology of PTEN loss leading to constitutive mTOR activation.

Show evidence (1 reference)

PMID:18781191 SUPPORT Other

"Concomitant with improved understanding of the biology of PTEN and the PI3K/Akt/mTOR pathway, inhibitors of this pathway are being developed as anticancer agents. These medications could have applications for patients with PHTS, for whom no medical options currently exist."

Establishes the rationale for mTOR/PI3K inhibitor therapy in PTEN hamartoma tumor syndrome based on the underlying molecular mechanism. Note: this is speculative expert opinion from a 2008 review, not clinical trial data.

Genetic Counseling

Action: genetic counseling MAXO:0000079

Genetic counseling is recommended for all patients with suspected or confirmed Cowden syndrome and their at-risk family members, informing testing decisions, cancer risks, and surveillance strategies.

Show evidence (1 reference)

PMID:31433956 SUPPORT Human Clinical

"Timely diagnosis and understanding the natural history of PHTS are vital because early recognition enables gene-informed management, particularly as related to high-risk cancer surveillance and addressing the neurodevelopmental symptoms."

Highlights the importance of genetic diagnosis enabling gene-informed counseling and management in PHTS/Cowden syndrome.

{ }

Source YAML

click to show

name: Cowden Syndrome
creation_date: "2026-03-19T00:00:00Z"
updated_date: "2026-03-19T00:00:00Z"
category: Mendelian
disease_term:
  preferred_term: Cowden syndrome
  term:
    id: MONDO:0016063
    label: Cowden disease
synonyms:
  - Cowden disease
  - Multiple hamartoma syndrome
parents:
  - Autosomal dominant hereditary syndrome
  - Hereditary cancer syndrome
  - PTEN hamartoma tumor syndrome
prevalence:
  - population: Global clinically recognized populations
    percentage: 1 in 200,000
    notes: >-
      Cowden syndrome is typically reported as affecting about 1 in 200,000
      individuals or live births in clinically recognized populations, although
      this likely underestimates true PTEN-hamartoma-spectrum burden because
      phenotypic expression is variable.
    evidence:
      - reference: PMID:21177507
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Germline loss-of-function phosphatase and tensin homolog gene (PTEN) mutations cause 80% of Cowden syndrome, a rare autosomal-dominant disorder (1 in 200,000 live births)"
        explanation: This JAMA study explicitly states the standard prevalence estimate for Cowden syndrome.
      - reference: PMID:29469739
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Cowden syndrome affects 1:200,000 individuals."
        explanation: This review-style clinical report independently gives the same population estimate.
has_subtypes:
  - name: Cowden Syndrome 1 (PTEN)
    description: >
      Classic Cowden syndrome caused by germline loss-of-function mutations in PTEN on
      chromosome 10q22-23, accounting for approximately 80% of cases meeting strict
      clinical diagnostic criteria. Mutations include nonsense, frameshift, missense,
      splice-site variants, and large deletions.
    evidence:
      - reference: PMID:24136893
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Although it was initially reported that approximately 80% of patients with Cowden syndrome had an identifiable germline PTEN mutation, more recent work has shown these diagnostic criteria to be far less specific."
        explanation: "Establishes PTEN mutation as the predominant genetic cause in Cowden syndrome 1, noting that original ~80% frequency estimates derived from clinically ascertained cohorts."
  - name: Cowden Syndrome 2 (KLLN)
    description: >
      Cowden syndrome caused by germline epigenetic silencing (promoter hypermethylation)
      of KILLIN (KLLN), a p53-co-regulated tumor suppressor transcribed from the same
      bidirectional promoter as PTEN. KLLN methylation down-regulates KILLIN expression
      and is associated with increased breast and renal cancer risk.
    evidence:
      - reference: PMID:21177507
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Germline KILLIN methylation is common among patients with Cowden syndrome or Cowden-like syndrome and is associated with increased risks of breast and renal cancer over PTEN mutation-positive individuals."
        explanation: "Defines KLLN germline epigenetic silencing as the second major cause of Cowden/Cowden-like syndrome, conferring higher breast and kidney cancer risk than PTEN mutation alone."
  - name: Cowden Syndrome 3 (PIK3CA)
    description: >
      Cowden syndrome caused by activating germline mutations in PIK3CA, the catalytic
      subunit of PI3-kinase. PIK3CA mutations are found in approximately 8.8% of PTEN
      mutation-negative Cowden syndrome individuals and result in elevated PIP3 and
      activated AKT, mimicking PTEN loss.
    evidence:
      - reference: PMID:23246288
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Our observations suggest that PIK3CA and AKT1 are CS susceptibility genes."
        explanation: "Identifies PIK3CA germline mutations as a causative alternative to PTEN in Cowden syndrome 3, acting through the same PI3K/AKT signaling axis."
  - name: Cowden Syndrome 4 (SDHB)
    description: >
      Cowden syndrome caused by germline mutations in succinate dehydrogenase subunit B
      (SDHB). SDH mutations alter mitochondrial metabolism, stabilize HIF-1alpha through
      pseudohypoxia, and activate downstream PI3K/AKT/MAPK signaling in the absence of
      PTEN mutation.
    evidence:
      - reference: PMID:18678321
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Germline SDH mutations/variants occur in a subset of PTEN mutation-negative CS/CS-like individuals and are associated with increased frequencies of breast, thyroid, and renal cancers beyond those conferred by germline PTEN mutations."
        explanation: "Establishes SDHB germline mutations as a causative factor in Cowden/Cowden-like syndrome in PTEN-mutation-negative individuals with elevated cancer risk."
pathophysiology:
  - name: PTEN Loss and PI3K/AKT/mTOR Pathway Activation
    description: >
      PTEN (phosphatase and tensin homolog) is a tumor suppressor that dephosphorylates
      phosphatidylinositol-3,4,5-trisphosphate (PIP3) to PIP2, thereby inhibiting the
      PI3K/AKT/mTOR signaling axis. Germline loss-of-function mutations in PTEN lead to
      constitutive accumulation of PIP3 and unopposed activation of AKT and downstream
      mTOR complex 1 (mTORC1), resulting in excessive cell proliferation, survival, and
      growth that underlies hamartoma formation and elevated cancer risk across multiple
      organ systems.
    cell_types:
      - preferred_term: Epithelial cell
        term:
          id: CL:0000066
          label: epithelial cell
      - preferred_term: Fibroblast
        term:
          id: CL:0000057
          label: fibroblast
    biological_processes:
      - preferred_term: PI3K/AKT signaling
        term:
          id: GO:0043491
          label: phosphatidylinositol 3-kinase/protein kinase B signal transduction
        modifier: INCREASED
      - preferred_term: TOR signaling
        term:
          id: GO:0031929
          label: TOR signaling
        modifier: INCREASED
      - preferred_term: Cell proliferation
        term:
          id: GO:0008283
          label: cell population proliferation
        modifier: INCREASED
      - preferred_term: Negative regulation of apoptosis
        term:
          id: GO:0043066
          label: negative regulation of apoptotic process
        modifier: INCREASED
    evidence:
      - reference: PMID:18781191
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "PTEN is located on chromosome 10q22-23 and negatively regulates the prosurvival PI3K/Akt/mTOR pathway through its lipid phosphatase activity. Loss of PTEN activates this pathway and leads to increased cellular growth, migration, proliferation, and survival."
        explanation: "Directly establishes that PTEN loss leads to PI3K/AKT/mTOR hyperactivation driving cellular overgrowth, the central molecular mechanism of Cowden syndrome."
      - reference: PMID:30614812
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "The tumor suppressor phosphatase and tensin homolog (PTEN) classically counteracts the PI3K/AKT/mTOR signaling cascade. Germline pathogenic PTEN mutations cause PTEN hamartoma tumor syndrome (PHTS), featuring various benign and malignant tumors, as well as neurodevelopmental disorders such as autism spectrum disorder."
        explanation: "Confirms PTEN's role as a counterbalance to PI3K/AKT/mTOR and links germline PTEN mutations to the full PHTS spectrum including Cowden syndrome."
    downstream:
      - target: Hamartoma Formation
        causal_link_type: DIRECT
      - target: Increased Cancer Risk
        causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - name: Hamartoma Formation
    description: >
      Constitutive activation of PI3K/AKT/mTOR signaling in multiple cell lineages drives
      the abnormal but organized proliferation of tissue elements native to the affected
      site, producing hamartomas. In Cowden syndrome these manifest as mucocutaneous
      trichilemmomas, papillomatous papules, acral keratoses, gastrointestinal hamartomatous
      polyps, and thyroid adenomas. The hamartomas are histologically benign but serve as
      a marker of systemic PTEN dysfunction and elevated cancer predisposition.
    cell_types:
      - preferred_term: Keratinocyte
        term:
          id: CL:0000312
          label: keratinocyte
      - preferred_term: Thyroid follicular cell
        term:
          id: CL:0002258
          label: thyroid follicular cell
    biological_processes:
      - preferred_term: Hamartomatous cell proliferation
        term:
          id: GO:0008283
          label: cell population proliferation
        modifier: INCREASED
    evidence:
      - reference: PMID:18781191
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "The PTEN hamartoma tumor syndromes (PHTS) are a collection of rare clinical syndromes characterized by germline mutations of the tumor suppressor PTEN. These syndromes are driven by cellular overgrowth, leading to benign hamartomas in virtually any organ."
        explanation: "Confirms that PTEN loss drives cellular overgrowth leading to hamartomas across organ systems, which is the hallmark of Cowden syndrome pathology."
    downstream:
      - target: Increased Cancer Risk
        causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - name: Increased Cancer Risk
    description: >
      The same PI3K/AKT/mTOR over-activation that drives benign hamartoma formation also
      confers markedly elevated lifetime risks for malignancies. The cumulative lifetime
      risk in PTEN mutation carriers includes breast cancer (~77-85%), follicular/papillary
      thyroid cancer (~35-38%), endometrial cancer (~28%), renal cell carcinoma (~34%),
      and colorectal cancer (~9-16%). Second-hit somatic mutations or epigenetic silencing
      of the remaining wild-type PTEN allele accelerate neoplastic progression.
    biological_processes:
      - preferred_term: Cell proliferation
        term:
          id: GO:0008283
          label: cell population proliferation
        modifier: INCREASED
    evidence:
      - reference: PMID:23335809
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Cumulative cancer risks at age 70 were 85% (95% CI 70% to 95%) for any cancer, 77% (95% CI 59% to 91%) for female breast cancer, and 38% (95% CI 25% to 56%) for thyroid cancer."
        explanation: "Quantifies the markedly elevated cumulative cancer risks in PTEN mutation carriers, establishing the clinical significance of increased cancer risk in PHTS/Cowden syndrome."
      - reference: PMID:32533092
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "The projected estimated lifetime risks of cancer in individuals with PHTS range from 85 to 89% for any cancer, 67 to 85% for female breast cancer, 6 to 38% for thyroid cancer, 2 to 28% for endometrial cancer, 2 to 34% for renal cancer, 9 to 20% for colorectal cancer and 0 to 6% for melanoma."
        explanation: "Provides European expert consensus estimates for organ-specific lifetime cancer risks in PHTS/Cowden syndrome, supporting the multi-organ cancer predisposition mechanism."

phenotypes:
  - category: Clinical
    name: Mucocutaneous Lesions
    description: >
      Pathognomonic mucocutaneous findings include multiple facial trichilemmomas
      (benign hamartomas of the hair follicle outer root sheath), acral and plantar
      keratoses, and papillomatous papules of the oral mucosa (cobblestone appearance).
      These lesions are present in more than 90% of adult Cowden syndrome patients and
      are the most distinctive clinical features of the syndrome.
    phenotype_term:
      preferred_term: Skin hamartoma
      term:
        id: HP:0010566
        label: Hamartoma
    evidence:
      - reference: PMID:17526800
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Cowden Syndrome (CS), an adult-onset condition recognised by mucocutaneous signs, with a risk of cancers, in particular those of the thyroid and breast."
        explanation: "Establishes mucocutaneous signs as the defining clinical feature of Cowden syndrome in PTEN mutation carriers."
  - category: Clinical
    name: Macrocephaly
    description: >
      Megalencephaly or macrocephaly (occipitofrontal circumference ≥ 97th percentile)
      is among the most prevalent features of PTEN-associated disorders, occurring in
      approximately 80% of affected individuals. It reflects PTEN's role in regulating
      neuronal cell size and cortical structure and is a prominent feature of
      Bannayan-Riley-Ruvalcaba syndrome, the childhood-onset form of PHTS.
    phenotype_term:
      preferred_term: Macrocephaly
      term:
        id: HP:0000256
        label: Macrocephaly
    evidence:
      - reference: PMID:17526800
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Bannayan-Riley-Ruvalcaba syndrome (BRRS), with childhood onset, macrocephaly, lipomas and developmental delay, and Cowden Syndrome (CS), an adult-onset condition recognised by mucocutaneous signs, with a risk of cancers, in particular those of the thyroid and breast."
        explanation: "Documents macrocephaly as a characteristic feature across the PTEN mutation phenotypic spectrum, particularly in the childhood-onset BRRS form."
  - category: Clinical
    name: Breast Cancer Risk
    description: >
      PTEN mutation carriers face a lifetime breast cancer risk of approximately 77-85%,
      with both invasive carcinoma and benign fibrocystic changes being common. Risk
      management includes enhanced surveillance with annual MRI from age 30 and
      mammography from age 40, or prophylactic mastectomy.
    phenotype_term:
      preferred_term: Breast carcinoma
      term:
        id: HP:0003002
        label: Breast carcinoma
    evidence:
      - reference: PMID:23335809
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Elevated SIRs were found mainly for female breast cancer (39.1, 95% CI 24.8 to 58.6), thyroid cancer in women (43.2, 95% CI 19.7 to 82.1) and in men (199.5, 95% CI 106.39 to 342.03), melanoma in women (28.3, 95% CI 7.6 to 35.4) and in men (39.4, 95% CI 10.6 to 100.9), and endometrial cancer (48.7, 95% CI 9.8 to 142.3)."
        explanation: "Demonstrates markedly elevated standardized incidence ratios (SIR 39.1) for breast cancer in female PTEN mutation carriers, confirming the substantially increased breast cancer risk in Cowden syndrome."
  - category: Clinical
    name: Thyroid Abnormalities
    description: >
      Non-medullary thyroid cancer (follicular and papillary subtypes) occurs in
      approximately 35% of PTEN mutation carriers. Benign thyroid conditions including
      multinodular goiter, follicular adenoma, and Hashimoto thyroiditis are also
      common; up to 75% of individuals develop some thyroid disease.
    phenotype_term:
      preferred_term: Thyroid carcinoma
      term:
        id: HP:0002890
        label: Thyroid carcinoma
    evidence:
      - reference: PMID:32533092
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "There is strong evidence of an increased risk of thyroid carcinoma in PHTS with evidence that this can arise at relatively young ages."
        explanation: "Confirms strong clinical evidence for increased thyroid carcinoma risk in PTEN hamartoma tumor syndrome/Cowden syndrome."
  - category: Clinical
    name: Uterine Cancer Risk
    description: >
      Germline PTEN mutations confer a lifetime risk of endometrial cancer of approximately
      28%, substantially higher than the general population risk (~3%). The endometrium
      is particularly sensitive to PTEN loss because somatic PTEN mutations are the most
      common alteration in sporadic endometrial cancers.
    phenotype_term:
      preferred_term: Endometrial carcinoma
      term:
        id: HP:0012114
        label: Endometrial carcinoma
    evidence:
      - reference: PMID:23335809
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Elevated SIRs were found mainly for female breast cancer (39.1, 95% CI 24.8 to 58.6), thyroid cancer in women (43.2, 95% CI 19.7 to 82.1) and in men (199.5, 95% CI 106.39 to 342.03), melanoma in women (28.3, 95% CI 7.6 to 35.4) and in men (39.4, 95% CI 10.6 to 100.9), and endometrial cancer (48.7, 95% CI 9.8 to 142.3)."
        explanation: "Documents a substantially elevated standardized incidence ratio (SIR 48.7) for endometrial cancer in PHTS, confirming uterine cancer as a major cancer risk in Cowden syndrome."
  - category: Clinical
    name: Lhermitte-Duclos Disease
    description: >
      Lhermitte-Duclos disease (LDD, dysplastic gangliocytoma of the cerebellum) is a
      pathognomonic central nervous system manifestation of Cowden syndrome, characterized
      by replacement of normal Purkinje cells with dysplastic ganglion cells. A systematic
      review of 302 LDD cases found that 32.8% were associated with Cowden syndrome and
      19.9% had confirmed PTEN mutation. Symptoms include headache (57.6%) and cerebellar
      ataxia (36.1%); the radiologic "tiger-stripe" appearance on MRI is pathognomonic.
    phenotype_term:
      preferred_term: Lhermitte-Duclos disease
      term:
        id: HP:0500009
        label: Dysplastic gangliocytoma of the cerebellum
    evidence:
      - reference: PMID:37810307
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Lhermitte-Duclos disease (LDD) is a rare tumor, with only about 300 reported cases. It often shows comorbidity with Cowden syndrome (CS); however, it can occur by itself."
        explanation: "Confirms the well-established association between Lhermitte-Duclos disease and Cowden syndrome in a systematic review of 302 cases, with 32.8% of LDD showing CS comorbidity."
  - category: Clinical
    name: Gastrointestinal Hamartomatous Polyps
    description: >
      Hamartomatous polyps of the gastrointestinal tract occur throughout the GI tract
      in more than 90% of individuals with Cowden syndrome. They are typically benign
      but may cause bleeding or obstruction, and are associated with a modestly increased
      colorectal cancer risk (~9-16% lifetime).
    phenotype_term:
      preferred_term: Hamartomatous intestinal polyposis
      term:
        id: HP:0004390
        label: Hamartomatous polyposis
    evidence:
      - reference: PMID:32533092
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Polyps are common in PHTS, and these are typically hamartomas, although other types can also occur."
        explanation: "Confirms hamartomatous GI polyps as a common feature of PTEN hamartoma tumor syndrome/Cowden syndrome."

genetic:
  - name: PTEN
    gene_term:
      preferred_term: PTEN
      term:
        id: hgnc:9588
        label: PTEN
    association: Causative
    inheritance:
      - name: Autosomal dominant
        inheritance_term:
          preferred_term: Autosomal dominant inheritance
          term:
            id: HP:0000006
            label: Autosomal dominant inheritance
        evidence:
          - reference: PMID:21194675
            supports: SUPPORT
            evidence_source: HUMAN_CLINICAL
            snippet: "Cowden syndrome (CS) and Bannayan-Riley-Ruvalcaba syndrome are allelic, defined by germline PTEN mutations, and collectively referred to as PTEN hamartoma tumor syndrome."
            explanation: "Establishes autosomal dominant germline PTEN mutations as the cause of Cowden syndrome: each affected generation inherits one pathogenic allele."
    notes: >
      Germline loss-of-function mutations in PTEN (MIM 601728) on chromosome 10q22-23
      are identified in approximately 80% of patients meeting strict clinical diagnostic
      criteria for Cowden syndrome. Mutations include nonsense, frameshift, missense,
      splice-site variants, and large deletions.
    evidence:
      - reference: PMID:21194675
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Cowden syndrome (CS) and Bannayan-Riley-Ruvalcaba syndrome are allelic, defined by germline PTEN mutations, and collectively referred to as PTEN hamartoma tumor syndrome."
        explanation: "Establishes PTEN germline mutations as the defining genetic cause of Cowden syndrome in a large prospective cohort of 3042 probands."
  - name: KLLN
    gene_term:
      preferred_term: KLLN
      term:
        id: hgnc:37212
        label: KLLN
    association: Causative
    inheritance:
      - name: Autosomal dominant
        inheritance_term:
          preferred_term: Autosomal dominant inheritance
          term:
            id: HP:0000006
            label: Autosomal dominant inheritance
        evidence:
          - reference: PMID:21177507
            supports: SUPPORT
            evidence_source: HUMAN_CLINICAL
            snippet: "Germline KILLIN methylation is common among patients with Cowden syndrome or Cowden-like syndrome and is associated with increased risks of breast and renal cancer over PTEN mutation-positive individuals."
            explanation: "Confirms KLLN/KILLIN germline epigenetic silencing as a heritable mechanism in Cowden syndrome 2, transmitted in an autosomal dominant pattern through the PTEN-KLLN bidirectional promoter locus."
    notes: >
      Promoter hypermethylation (epimutation) or deletion of KILLIN (KLLN), a p53
      co-regulated tumor suppressor transcribed in the opposite direction from the same
      PTEN promoter, is found in approximately 37% of Cowden/Cowden-like syndrome patients
      lacking PTEN coding mutations. KLLN down-regulation by 250-fold leads to loss of
      p53-activated DNA synthesis inhibition and apoptosis, conferring higher breast and
      kidney cancer risk than PTEN mutation alone.
    evidence:
      - reference: PMID:21177507
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Germline KILLIN methylation is common among patients with Cowden syndrome or Cowden-like syndrome and is associated with increased risks of breast and renal cancer over PTEN mutation-positive individuals."
        explanation: "Establishes KLLN germline methylation as a distinct molecular subtype of Cowden syndrome with measurably elevated cancer risks."
  - name: PIK3CA
    gene_term:
      preferred_term: PIK3CA
      term:
        id: hgnc:8975
        label: PIK3CA
    association: Causative
    inheritance:
      - name: Autosomal dominant
        inheritance_term:
          preferred_term: Autosomal dominant inheritance
          term:
            id: HP:0000006
            label: Autosomal dominant inheritance
        evidence:
          - reference: PMID:23246288
            supports: SUPPORT
            evidence_source: HUMAN_CLINICAL
            snippet: "Our observations suggest that PIK3CA and AKT1 are CS susceptibility genes."
            explanation: "Establishes PIK3CA germline mutations as a cause of Cowden syndrome 3 through direct activation of the PI3K/AKT pathway, with autosomal dominant inheritance."
    notes: >
      Activating germline mutations in PIK3CA (the catalytic p110alpha subunit of PI3-kinase)
      are identified in approximately 8.8% of PTEN mutation-negative Cowden syndrome
      individuals and result in significantly increased phospho-AKT and cellular PIP3.
      This directly activates the same downstream pathway affected by PTEN loss.
    evidence:
      - reference: PMID:23246288
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "We report that 8 of 91 (8.8%) unrelated CS individuals without germline PTEN mutations carried 10 germline PIK3CA mutations (7 missense, 1 nonsense, and 2 indels) and 2 (2.2%) AKT1 mutations. These mutations result in significantly increased P-Thr308-AKT and increased cellular PIP3."
        explanation: "Directly identifies PIK3CA germline mutations in Cowden syndrome patients lacking PTEN mutations, confirming PIK3CA as a causative gene in Cowden syndrome 3."
  - name: SDHB
    gene_term:
      preferred_term: SDHB
      term:
        id: hgnc:10681
        label: SDHB
    association: Causative
    inheritance:
      - name: Autosomal dominant
        inheritance_term:
          preferred_term: Autosomal dominant inheritance
          term:
            id: HP:0000006
            label: Autosomal dominant inheritance
        evidence:
          - reference: PMID:18678321
            supports: SUPPORT
            evidence_source: HUMAN_CLINICAL
            snippet: "Germline SDH mutations/variants occur in a subset of PTEN mutation-negative CS/CS-like individuals and are associated with increased frequencies of breast, thyroid, and renal cancers beyond those conferred by germline PTEN mutations."
            explanation: "Establishes SDHB/SDHD germline mutations as heritable CS4/CS5 causes via autosomal dominant inheritance, manifesting increased breast, thyroid, and renal cancer risk."
    notes: >
      Germline mutations in SDHB (succinate dehydrogenase subunit B) occur in approximately
      13.5% of Cowden/Cowden-like individuals with mitochondrial dysfunction markers and no
      PTEN alteration (10/74 SDH-variants in 375 PTEN-negative CS/CS-like individuals).
      SDH mutations cause mitochondrial dysfunction, pseudohypoxia via HIF-1alpha stabilization,
      and activation of AKT/MAPK signaling downstream of PTEN.
    evidence:
      - reference: PMID:18678321
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Germline SDH mutations/variants occur in a subset of PTEN mutation-negative CS/CS-like individuals and are associated with increased frequencies of breast, thyroid, and renal cancers beyond those conferred by germline PTEN mutations."
        explanation: "Establishes SDHB germline mutations as a causative factor in Cowden syndrome 4, found in PTEN-mutation-negative individuals with elevated cancer risk."

treatments:
  - name: Enhanced Cancer Surveillance
    description: >
      PTEN mutation carriers require life-long intensified surveillance protocols: annual
      MRI breast screening from age 30, annual thyroid ultrasound from age 18, renal
      ultrasound every 2 years from age 40, and baseline colonoscopy at age 35-40.
      These recommendations are based on European expert consensus (ERN GENTURIS, 2020).
    treatment_term:
      preferred_term: cancer surveillance
      term:
        id: MAXO:0000126
        label: cancer screening
    evidence:
      - reference: PMID:32533092
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Recommendations were put forward for surveillance for breast, thyroid and renal cancers. Limited recommendations were developed for other sites including endometrial, colon and skin."
        explanation: "Provides evidence-based surveillance recommendations for PHTS/Cowden syndrome from the European Reference Network for Genetic Tumour Risk Syndromes."
  - name: Prophylactic Mastectomy
    description: >
      Risk-reducing bilateral mastectomy reduces breast cancer risk by more than 90% in
      PTEN mutation carriers with high personal or family risk. It is offered as an option
      after careful counseling regarding elevated lifetime risk, using the same approach
      as for BRCA1/BRCA2 carriers.
    treatment_term:
      preferred_term: prophylactic mastectomy
      term:
        id: MAXO:0000004
        label: surgical procedure
    evidence:
      - reference: PMID:32533092
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Risk reduction surgery should be offered using the same considerations as for women with germline BRCA1/BRCA2 pathogenic variants"
        explanation: "Supports offering prophylactic mastectomy in PTEN mutation carriers following the same approach as for BRCA1/BRCA2, given comparable breast cancer risk levels."
  - name: mTOR Inhibitor Therapy
    description: >
      Everolimus (RAD001), an mTORC1 inhibitor, targets the hyperactivated PI3K/AKT/mTOR
      pathway in Cowden syndrome. The rationale for PI3K pathway inhibitors in PHTS stems
      directly from the underlying molecular pathophysiology of PTEN loss leading to
      constitutive mTOR activation.
    treatment_term:
      preferred_term: mTOR inhibitor pharmacotherapy
      term:
        id: MAXO:0000058
        label: pharmacotherapy
    evidence:
      - reference: PMID:18781191
        supports: SUPPORT
        evidence_source: OTHER
        snippet: "Concomitant with improved understanding of the biology of PTEN and the PI3K/Akt/mTOR pathway, inhibitors of this pathway are being developed as anticancer agents. These medications could have applications for patients with PHTS, for whom no medical options currently exist."
        explanation: "Establishes the rationale for mTOR/PI3K inhibitor therapy in PTEN hamartoma tumor syndrome based on the underlying molecular mechanism. Note: this is speculative expert opinion from a 2008 review, not clinical trial data."
  - name: Genetic Counseling
    description: >
      Genetic counseling is recommended for all patients with suspected or confirmed
      Cowden syndrome and their at-risk family members, informing testing decisions,
      cancer risks, and surveillance strategies.
    treatment_term:
      preferred_term: genetic counseling
      term:
        id: MAXO:0000079
        label: genetic counseling
    evidence:
      - reference: PMID:31433956
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Timely diagnosis and understanding the natural history of PHTS are vital because early recognition enables gene-informed management, particularly as related to high-risk cancer surveillance and addressing the neurodevelopmental symptoms."
        explanation: "Highlights the importance of genetic diagnosis enabling gene-informed counseling and management in PHTS/Cowden syndrome."